Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
about
Pediatric Statin Administration: Navigating a Frontier with Limited DataStatin-associated memory loss: analysis of 60 case reports and review of the literature.Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties.Rhabdomyolysis and HMG-CoA reductase inhibitors.Cognitive Impairment and Age-Related Vision Disorders: Their Possible Relationship and the Evaluation of the Use of Aspirin and Statins in a 65 Years-and-Over Sardinian PopulationApplication of mixture experimental design to simvastatin apparent solubility predictions in the microemulsifion formed by self-microemulsifying.Pharmacological effects of lipid-lowering drugs on circulating adipokines.Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations.Bioerodible devices for intermittent release of simvastatin acid.Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects.Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells.Statin use after intracerebral hemorrhage: a 10-year nationwide cohort study.Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins.Local delivery of controlled-release simvastatin/PLGA/HAp microspheres enhances bone repair.Molecular basis for statin-induced muscle toxicity: implications and possibilities.Simvastatin induces a central hypotensive effect via Ras-mediated signalling to cause eNOS up-regulation.Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway.Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons.Poloxamine-cyclodextrin-simvastatin supramolecular systems promote osteoblast differentiation of mesenchymal stem cells.Statins Determination: A Review of Electrochemical Techniques.Simvastatin induces osteogenic differentiation of murine embryonic stem cells.Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress.The influence of bile salts on the distribution of simvastatin in the octanol/buffer system.Simvastatin and lovastatin, but not pravastatin, interact with MDR1.Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification.Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs.Intratracheal instillation of pravastatin for the treatment of murine allergic asthma: a lung-targeted approach to deliver statins.Simvastatin-associated memory loss.Statins induce suppressor of cytokine signaling-3 in macrophages.Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform.Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.Core – Shell pH-Responsive Poly(Vinylpyrrolidone)-Block-Poly(Ethylene Glycol)-Block-Poly(Methacrylic Acid) Coated Magnetic Nanoparticle as a Carrier for Delivery of Poorly Water-Soluble LovastatinStatin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters
P2860
Q28068014-564C6DE5-755C-4666-926E-0296CFA29807Q33967399-E86058C4-39FE-47CC-A70E-462A221B993EQ34376402-5365B3CA-E5D6-4E10-B35F-32D196B7DEEEQ34382555-97BD157A-92DC-4F7C-A09B-A48A6CCBEC80Q34471418-26943FDF-B5B1-4E01-9F33-502F0DE68734Q34692340-858609D8-0128-45B7-BC1F-95F497116F83Q34877922-73E95F30-CA56-4CDE-BE58-19B968AA297FQ35028546-CA2C2353-05EF-4BBE-ADC3-92671F719042Q35642416-F233E126-1ECA-4911-9B87-2A7041C2061DQ36398292-3F8DCB0A-96D4-4C4D-ACE5-7B90A53FB313Q36553647-7F42AF13-14F3-4D82-88F6-2E8D250BDF20Q36735614-8609392E-D618-4106-A2AB-8FB2C0AF823BQ36903009-9E44B65C-C8E7-4681-9CCF-AB6CB400EB02Q36906404-307C2955-F56F-4937-AA76-B64CC5918004Q37233315-B95E1341-F9DD-4608-AA88-B563FBF9C3E5Q37235648-8C26D93E-9B39-44FF-A1CB-E258921FFC73Q37237168-A8290464-93D0-4B41-BB29-904889F6438AQ38795202-70DABB09-7C67-45FB-B379-8B7C0BF61359Q38841393-F621AEBB-F9C6-4E4C-96EA-4AA5FE9B3DDCQ39162050-78DB4402-660A-4C7E-93A2-41732CFEE3F8Q39332686-44F1E5A2-D858-4AE2-AF53-3D0FA5A919E9Q39861887-BFE228D7-BD07-472A-94E1-0ECE0BFDC6C0Q39963963-28B88E14-2D32-4DB5-9F7A-441018FD35F7Q40703785-C1A5B1C2-56B1-45C2-BE6E-AEBF329C1BB2Q40743825-EEE240FB-CAD1-428A-9B7B-7FB77F6A8E8DQ41692388-61C033DE-C823-48B6-B51E-B59BE4E427E7Q42507291-3BB50286-E71C-4041-9D86-00CDBA72C058Q42530785-D9DDD9A6-AFBD-45F8-A778-CFF9BF201D7DQ43636346-07B1BF1B-77BF-4C44-8B0A-2774803515F7Q44673403-64A747A3-8718-4618-AE3F-2A4C2458644FQ48347873-A59B5C8A-88B5-4759-8151-2714456C9769Q48832403-BE77374D-089A-4112-8005-3CAE032EFB77Q57351421-45A6C689-D9CB-4EDA-9004-35E3C159099FQ59126976-C0749851-64BD-4269-B063-2145656F2930
P2860
Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
description
1991 nî lūn-bûn
@nan
1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@ast
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@en
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@nl
type
label
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@ast
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@en
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@nl
prefLabel
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@ast
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@en
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@nl
P2093
P356
P1476
Relative lipophilicities, solu ...... , mevastatin, and simvastatin.
@en
P2093
Mahoney EM
Ranadive SA
Serajuddin AT
P304
P356
10.1002/JPS.2600800905
P407
P577
1991-09-01T00:00:00Z